Vutiglabridin（中文译名未知），开发代号HSG4112，是一种外消旋的有机化合物，化学式为C22H26O4，为实验性抗肥胖药物，是光甘草定的结构类似物。[1][2][3]
事实速览 法律規範狀態, 法律規範 ...
HSG4112 |
|
| 法律規範 |
|
|---|
|
2-(8,8-Dimethyl-3,4,9,10-tetrahydro-2H-pyrano[2,3-h]chromen-3-yl)-5-ethoxyphenol
|
| CAS号 | 1800188-47-9  Y |
|---|
| PubChem CID | |
|---|
| UNII | |
|---|
|
| 化学式 | C22H26O4 |
|---|
| 摩尔质量 | 354.45 g·mol−1 |
|---|
| 3D模型（JSmol） | |
|---|
OC1=CC(OCC)=CC=C1C2COC=3C(=CC=C4OC(C)(C)CCC43)C2
|
关闭
它可以5-羟基-2,2-二甲基-2H-1-苯并呋喃-6-甲醛为原料经多步反应制得。[4]
Hyeon, Jooseung; Lee, Jihan; Kim, Eunju; Lee, Hyeong Min; Kim, Kwang Pyo; Shin, Jaejin; Park, Hyung Soon; Lee, Yun-Il; Nam, Chang-Hoon. Vutiglabridin exerts anti-ageing effects in aged mice through alleviating age-related metabolic dysfunctions. Experimental Gerontology. October 2023, 181: 112269. doi:10.1016/j.exger.2023.112269 
. Na, Joo Young; Yoon, Deok Yong; Yoo, Hyounggyoon; Lee, SeungHwan; Yu, Kyung‐Sang; Jang, In‐Jin; Yoo, Sang‐Ku; Kim, Youngah; Oh, Jaeseong. Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study. Clinical and Translational Science. November 2022, 15 (11): 2744–2757. ISSN 1752-8054. PMC 9652434 . doi:10.1111/cts.13401 （英语）. Choi, Leo Sungwong; Jo, In Geun; Kang, Ku Suk; Im, Jeong Ho; Kim, Jiyoung; Kim, Jinyoung; Chung, Jin Wook; Yoo, Sang-Ku. Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity. International Journal of Obesity. January 2021, 45 (1): 130–142 [2023-12-14]. ISSN 1476-5497. doi:10.1038/s41366-020-00686-1 . （原始内容存档于2023-12-20） （英语）. Yoo, Sang Ku; Chung, Jin Wook; Jo, In Geun; Im, Jeong Ho; Kang, Ku Suk; Kim, Jin Young. Pyranochromenyl-phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease. 2015. WO2015099392（韓文） / 2014. CN105849111A（中文） / 2016. US2016272650A1（英文）.
